Back to Journals » The Application of Clinical Genetics » Volume 7

Wiskott–Aldrich syndrome: diagnosis, current management, and emerging treatments

Authors Buchbinder D, Nugent D, Fillipovich A

Received 28 November 2013

Accepted for publication 31 December 2013

Published 3 April 2014 Volume 2014:7 Pages 55—66

DOI https://doi.org/10.2147/TACG.S58444

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3


David Buchbinder,1 Diane J Nugent,1 Alexandra H Fillipovich2

1Division of Hematology, Children's Hospital of Orange County, Orange, CA, USA; 2Division of Immunology, Cincinnati Children's Hospital, Cincinnati, OH, USA

Abstract: Wiskott–Aldrich syndrome (WAS) is a rare X-linked primary immunodeficiency disorder characterized by the triad of eczema, thrombocytopenia, and severe and often recurrent infections. Despite the rarity of this disorder, our understanding of the molecular and cellular pathogenesis of WAS has continued to increase. Advances in the use of diagnostic tools, the provision of supportive care, and improvements in allogeneic hematopoietic stem cell transplantation have significantly reduced the morbidity and mortality associated with this disorder. Exciting advancements in the care of patients with WAS have also occurred, including the successful application of autologous gene-modified hematopoietic stem cell transplantation.

Keywords: primary immunodeficiency, Wiskott–Aldrich syndrome, hematopoietic stem cell transplantation, gene therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]